Thus, whereas using BRAF and MEK inhibitors in metastatic melanoma patients caused severe adverse events (reviewed in [66]), pharmacologically inhibiting MNK1/2 kinases represents a promising therapeutic option, as limited side-effects and toxicities are expected upon abrogation of MNK1/2 activity. The gene discussed is MKNK1; the disease is metastatic melanoma.